Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
CURE Pharmaceutical Holding Corp is a biopharmaceutical company focusing on the development and manufacturing of drug formulation and drug delivery technologies in novel dosage forms to improve drug safety, efficacy and patient adherence. Its technology platform includes oral dissolving film (ODF), and encapsulation systems (microCURE) compatible with ODF, chews, oral solutions, topical and transdermal dose forms. It is developing a 50,000IU, once per week, Vitamin D3 ODF for oral administration to be distributed in the United States and the MENA region. Its pharmaceutical drug program includes CUREfilm Blue and CUREfilm Canna.
Oxnard, CA, 93033